Navigation Links
KaloBios' KB001 Anti-Pseudomonas Antibody Study Published in Pediatric Pulmonology
Date:9/18/2013

underway of KB001-A as a potential non-antibiotic treatment to reduce airway inflammation and tissue damage in CF patients with chronic Pa infection," Dr. Molfino concluded.

The published study results showed a single intravenous dose of KB001 to have an acceptable safety profile and a trend toward a short-term reduction in markers of inflammation, particularly neutrophil elastase which has long been recognized as the main enzyme responsible for lung damage in CF patients. The investigators concluded that repeat-dosing studies are required to evaluate the durability of the anti-inflammatory effects and how treatment with KB001 might translate into clinical benefit.

KaloBios is currently enrolling patients in a Phase 2 multi-dose, randomized, double-blind, placebo-controlled clinical trial with KB001-A in CF patients chronically infected with Pa. This 180-patient study is intended to evaluate the efficacy and safety of repeat doses of KB001-A. The primary endpoint is time-to-need for antibiotics. To learn more about this study, including eligibility criteria, please visit www.clinicaltrials.gov.

About KaloBios

KaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies designed to treat severe life-threatening or debilitating diseases for which there is an unmet medical need, with a clinical focus on severe respiratory diseases and cancer.

Currently, KaloBios has three drug development programs:

  • KB003, an anti-GM-CSF mAb with potential to treat inflammatory diseases, is being developed for the treatment of severe asthma. Enrollment of 160 patients has been completed in a planned 150 patient Phase 2 study in the United States, Europe and Australia
    '/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
2. KaloBios Pharmaceuticals Completes Initial Public Offering
3. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
4. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
5. Bioassociate Announces Initiation of Coverage on KaloBios Pharmaceuticals, Inc.
6. KaloBios to Present at Future Leaders in the Biotech Industry Conference
7. KaloBios Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
8. KaloBios to Present at Needham Healthcare Conference
9. KaloBios Reports First Quarter 2013 Financial Results
10. KaloBios to Present at Stifel Healthcare Conference 2013
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... SAN MARCOS, Texas , Nov. 21, 2014 /PRNewswire/ ... industrial hemp containing low THC, announces they are now ... is comparable to Charlotte,s Web type strains grown in ... symptoms from other neurological disorders, such as Parkinson,s, MS, ... waiting for US laws to pass, because imported CBD ...
(Date:11/21/2014)... , Nov. 21, 2014  Abaxis, Inc. (NasdaqGS: ... instruments and consumables for the medical, research, and veterinary ... veterinary and research markets in the United ... stock purchase agreement to acquire 100% of QCR & ... based distribution organization. The transaction closed on November ...
(Date:11/21/2014)... MONTREAL , 21. November 2014 ... hat heute bekannt gegeben, dass ... – EMA) die Kennzeichnung als Orphan-Medizinprodukt ... Produktkandidat des Unternehmens zur Behandlung von ... eine seltene, stark beeinträchtigende genetische Krankheit, ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
... Inc. (NYSE: LDR) announced today that its Board of ... share for the second quarter of fiscal 2012. The dividend will ... on March 9, 2012. About Landauer ... services to determine occupational and environmental radiation exposure and is ...
... BRUSSELS, Feb. 28, 2012 Eli Lilly and Company (NYSE: ... global Innovation Starts Here initiative which supports Lilly,s commitment to ... the world. Two key components of this ... Innovation Fellowship Awards. Through both, Lilly scientists will collaborate with ...
Cached Medicine Technology:Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 2Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 3Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 4Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 5
(Date:11/21/2014)... CDT PLUS! 2015 represents ... includes everything needed to process dental insurance claims. ... , CDT 2015 codes are mandatory for reporting dental ... December 31, 2014. Dental professionals must use HIPAA mandated ... claims. There are significant changes in the CDT coding ...
(Date:11/21/2014)... 21, 2014 TopConsumerReviews.com recently awarded ... industry leader in the relief of depression ... feelings of sadness and depression each year and ... choices. Often, prescription drugs can produce worse side ... are expensive and require regular follow-up visits with ...
(Date:11/21/2014)... FL (PRWEB) November 21, 2014 According ... issued on June 11th, 2014, the inflating system ... rupture when the airbag inflates. The force of inflation ... shrapnel, and the metal shards may pierce the airbag’s ... vehicle’s cabin. , According to a Bloomberg Business ...
(Date:11/21/2014)... London, UK (PRWEB) November 21, 2014 ... only ISO verified healthcare professional panel, today announced two important ... appointment of Roni DasGupta as President of Market Research, Americas ... Market Research, Europe. , Ms. DasGupta joined M3 ... President and most recently Head of Sales. Roni has ...
(Date:11/21/2014)... Dennis Thompson HealthDay ... Injecting beads of gel into the wall of a still-beating ... with severe heart failure, according to a new study. ... oxygen levels and were able to walk hundreds of feet ... Douglas Mann. He is chief of the cardiovascular division at ...
Breaking Medicine News(10 mins):Health News:PMIC Announces CDT PLUS! 2015, the Ultimate Coding Reference for Dentists and Oral Surgeons 2Health News:Depression Relief Product Receives Top 5-Star Rating from TopConsumerReviews.com 2Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 2Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 3Health News:M3 Global Research Announces Leadership Team Promotions in US and EU 2Health News:Gel Implant Might Help Fight Heart Failure 2Health News:Gel Implant Might Help Fight Heart Failure 3
... to open blocked heart arteries a key question has ... expensive drug, abciximab, justified over use of the less-expensive ... be published in the current edition of Value in ... an e-publication, offers clinicians the first large-scale contemporary study ...
... On the Wings to Patient Safety: Innovative Solutions and Tools set ... ... Mich., Sept. 10 The Risk Management and,Patient Safety Institute (RM&PSI) ... conference. The RM&PSI, a,subsidiary of FinCor Holdings Inc. (http://www.fincorholdings.com ), ...
... accuracy and turn-around time for reimbursement, WAYNE, ... in,health information management (HIM) services and technologies, today,announced ... 2X. The key enhancement to PrecyseCode 2X is ... of the medical record,and greater efficiency and speed ...
... Wolf Haldenstein Obtain Third-Largest Settlement,in Securities Fraud Case ... Sept. 10 Judge Morris E.,Lasker of the ... has,granted final approval of a $52.5 million settlement ... Sepracor Inc., a,Massachusetts-based pharmaceutical company (Nasdaq: SEPR ...
... well known healthcare industry executive to start October ... Corporation,(NYSE: STE ) today announced that its ... 53, president and chief executive officer, effective,October 1, ... Company,s Board,effective that date. (Photo: http://www.newscom.com/cgi-bin/prnh/20070910/CLM134 ...
... Institute are the first to discover a mechanism that ... cycle and survival. Their research may result in identification ... , The results of the study appear ... PhD, assistant professor of hematology and oncology at Emory ...
Cached Medicine News:Health News:The Risk Management and Patient Safety Institute Announces Annual Health Care Risk Conference Dates 2Health News:Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals 2Health News:Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals 3Health News:$52.5 Million Settlement Against Sepracor Inc. Approved 2Health News:STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer 2Health News:STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer 3Health News:STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer 4Health News:STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer 5Health News:Emory researchers identify signaling protein for multiple myeloma 2Health News:Emory researchers identify signaling protein for multiple myeloma 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: